Receptor antagonist of NMDA and animal models of schizophrenia

Journal of Forensic Medicine

Volumn 25, Issue 6, 2009, Pages 443-446

  Bian, Shi Zhong ^a   Zhang, Jian ^a,b   Liu, Wei Li ^a   Sun, Zhi Hong ^a   Gu, Zhen Lun ^b,c   Jiang, Xiao Gang ^b,c  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Suzhou Institute of Chinese Materia Medica   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Forensic psychiatry; N methyl D aspartate; Receptors; Review publication type ; Schizophrenia

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMICALLY INDUCED DISORDER; CONSCIOUSNESS DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RAT; REVIEW; SCHIZOPHRENIA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CONSCIOUSNESS DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MICE; PHENCYCLIDINE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 76649133779     PISSN: 10045619     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1004-5619.2009.06.014     Document Type: Review

References (26)

1. Mouri A, Noda Y, Enomoto T, et al. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment[J]. Neurochem Int,2007, 51 (2-4):173-184.
2. [2] Shiigi Y, Casey DE. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates[J]. Psychopharmacology (Berl), 1999, 146 (1) : 67-72. (Pubitemid 29441115)
3. Paine TA, Carlezon WA. Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats[J]. Neuropharmacology,2009,56(4): 788-797.
4. Guo X, Hamilton PJ, Reish NJ, et al. Reduced expression of the NMDA receptor -interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia[J]. Neuropsychopharmacology, 2009, 34(7):1659-1672.
5. Mohn AR, Gainetdinov RR, Caron MG, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia[J]. Cell, 1999, 98 (4): 427-436.
6. Northoff G, Richter A, Bermpohl F, et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI[J]. Schizophr Res,2005,72(2-3):235-248.
7. [7] Javitt DC, Jayachandra M, Lindsley RW, et al. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP) [J]. Clin Neurophysiol, 2000, 111 (5): 833-836. (Pubitemid 30236429)
8. Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia[J]. Psychopharmacology (Berl), 2008, 200 (2): 217-230.
9. Wedzony K, Fijal K, Mackowiak M, et al. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia[J]. Neuroscience, 2008,153(4): 1370-1379.
10. [10] Krystal JH, D'Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development[J]. Psychopharmacology (Berl), 2003, 169(3-4):215-233. (Pubitemid 37264943)
11. [11] Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia [J]. Neuropsychopharmacology, 1999, 20(3):201-225. (Pubitemid 29067401)
12. [12] Bubeníková-Valesová V, Horácek J, Vrajová M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors[J]. Neurosci Biobehav Rev, 2008, 32(5):1014-1023. (Pubitemid 351756510)
13. Kilts CD. The changing roles and targets for animal models of schizophrenia[J]. Biol Psychiatry,2001,50(11): 845-855.
14. [14] Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine : role of sigma-1 receptors [J]. Neuropsychopharmacology,2007, 32(3):514-521. (Pubitemid 46271046)
15. Enomoto T, Noda Y, Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis [J]. Methods Find Exp Clin Pharmacol,2007,29(4):291-301.
16. Mouri A, Noda Y, Enomoto T, et al. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment[J]. Neurochem Int,2007,51 (2-4): 173-184.
17. Radonjić NV, Petronijević ND, Vucković SM, et al. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration[J]. Physiol Behav,2008, 93(3):437-443.
18. Nabeshima T, Mouri A, Murai R, et al. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine[J]. Ann N Y Acad Sci, 2006, 1086:160-168.
19. [20] Rung JP, Carlsson A, Rydén Markinhuhta K, et al. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005,29 (5) : 827-832. (Pubitemid 40897800)
20. Qi C, Zou H, Zhang R, et al. Age-related differential sensitivity to MK-801-induced locomotion and stereotypy in C57BL/6 mice [J]. Eur J Pharmacol, 2008, 580(1-2):161-168.
21. Manahan-Vaughan D, Wildförster V, Thomsen C, et al. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transport er-1(GlyT1)[J]. Eur J Neurosci,2008, 28(7) : 1342-1350.
22. [23] Shiigi Y, Casey DE. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates[J]. Psychopharmacology (Berl), 1999,146 (1) : 67-72. (Pubitemid 29441115)
23. Becker A, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity[J]. Prog Neuropsychopharmacol Biol Psychiatry,2004,28(8): 1267-1277.
24. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain[J]. Brain Res Rev, 2009,60(2):279-286.
25. Hunt MJ, Kessal K, Garcia R. Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats[J]. J Neurosci,2005,25(2):524-531.